Last updated: September 2, 2026
Pasireotide diaspartate is the active pharmaceutical ingredient in Novartis’s Signifor immediate-release product. The drug is a somatostatin receptor ligand approved for adults with Cushing’s disease when pituitary surgery is not an option or has not cured the disease. Its long-acting formulation, Signifor LAR, uses pasireotide pamoate and targets Cushing’s disease and acromegaly.
The commercial profile is niche and specialized. Demand is supported by rare endocrine diseases, limited treatment alternatives, and the need for medical therapy after unsuccessful surgery. Revenue potential is constrained by a small patient population, strong competition from established somatostatin analogues and cortisol-lowering drugs, hyperglycemia risk, injection requirements, and the absence of separately reported product sales from Novartis.
What is pasireotide diaspartate used to treat?
Pasireotide diaspartate is used primarily for Cushing’s disease. The drug binds multiple somatostatin receptor subtypes, with high affinity for somatostatin receptor subtype 5, which is commonly expressed in corticotroph pituitary tumors. Binding reduces adrenocorticotropic hormone secretion and can lower cortisol production.
The FDA approved Signifor injection in December 2012 for adults with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.[1]
The product is administered by subcutaneous injection twice daily. Signifor LAR is administered intramuscularly at longer intervals and is used in patients who require sustained treatment. Pasireotide pamoate is the long-acting salt form, while pasireotide diaspartate is associated with the immediate-release product.
Core products and indications
| Product |
Active form |
Delivery |
Principal indication |
Commercial role |
| Signifor injection |
Pasireotide diaspartate |
Subcutaneous, twice daily |
Cushing’s disease |
Initial FDA-approved product |
| Signifor LAR |
Pasireotide pamoate |
Intramuscular depot injection |
Acromegaly and Cushing’s disease in applicable markets |
Longer-acting commercial product |
| Generic pasireotide |
Not broadly established |
Complex injectable/depot technology |
Potential future competition |
Limited current evidence of market entry |
The clinical value proposition is strongest for patients who cannot undergo curative surgery, have persistent disease after surgery, or require medical control while awaiting another intervention.
How large is the pasireotide market?
The addressable market is small in patient numbers but commercially valuable on a per-patient basis. Cushing’s disease is a rare disorder, generally estimated at several cases per million people annually. Acromegaly is more prevalent than Cushing’s disease but remains an orphan endocrine condition relative to major pharmaceutical markets.
The relevant market is divided into two segments:
- Cushing’s disease medical therapy.
- Acromegaly treatment after surgery or inadequate response to first-line somatostatin analogues.
Pasireotide does not compete across the full endocrine market. It competes within treatment-resistant or treatment-ineligible subpopulations.
Competitive products
| Disease area |
Competing products |
Competitive relevance |
| Cushing’s disease |
Osilodrostat, mifepristone, ketoconazole, levoketoconazole, cabergoline |
Cortisol reduction, symptom control, or off-label pituitary-directed therapy |
| Acromegaly |
Octreotide LAR, lanreotide, pegvisomant, oral octreotide |
Established first-line and add-on treatments |
| Pituitary surgery |
Transsphenoidal surgery |
Preferred curative intervention when feasible |
| Emerging medical therapy |
Novel pituitary-directed and cortisol-lowering agents |
Potential pressure on long-term pasireotide use |
Acromegaly is the more established competitive market for somatostatin receptor ligands. Octreotide LAR and lanreotide have extensive clinical use and physician familiarity. Pasireotide is generally positioned after inadequate control with first-generation somatostatin analogues, which restricts its market to a later treatment line.
In Cushing’s disease, pasireotide competes with drugs that directly inhibit cortisol synthesis. Osilodrostat, approved by the FDA in 2020, has a direct cortisol-lowering mechanism and has increased competitive pressure in patients requiring rapid biochemical control.[4]
What are the main market drivers for pasireotide?
The main demand drivers are persistent endocrine disease, limited surgical options, and treatment failure with earlier therapies.
Unmet need after pituitary surgery
Surgery is generally the preferred treatment for pituitary-driven Cushing’s disease. A meaningful proportion of patients experience persistent or recurrent disease. These patients require medical therapy, repeat surgery, radiation, or bilateral adrenalectomy.
Pasireotide benefits from this treatment gap because it targets the pituitary source of adrenocorticotropic hormone. The drug is especially relevant where clinicians seek a tumor-directed therapy rather than an adrenal steroidogenesis inhibitor.
Long-term disease management
Cushing’s disease and acromegaly often require long-term treatment. Patients who cannot achieve biochemical control through surgery or first-line drugs may remain on chronic injectable therapy.
Long-term demand is offset by tolerability concerns. Hyperglycemia is a major known risk with pasireotide. The FDA label includes warnings concerning hyperglycemia, diabetes, bradycardia, QT prolongation, liver test abnormalities, and adrenal hormone suppression.[1,2]
Specialist prescribing
Treatment is concentrated among endocrinologists and tertiary referral centers. This supports targeted commercial activity but limits broad primary-care adoption. The specialist channel also creates a high evidence threshold. Physicians generally compare pasireotide against surgery, established somatostatin analogues, cortisol-lowering drugs, and combination regimens.
What clinical factors limit pasireotide revenue growth?
Hyperglycemia is the largest commercial constraint. Pasireotide has a stronger effect on glucose metabolism than several competing somatostatin analogues. Patients with preexisting diabetes or high metabolic risk may be poor candidates.
In the Phase III PASPORT-CUSHINGS study, pasireotide LAR demonstrated biochemical activity in Cushing’s disease, but glucose-related adverse events remained clinically relevant.[3] The label requires glucose monitoring and management during therapy.
Other commercial limitations include:
- Twice-daily administration for immediate-release Signifor.
- Intramuscular administration for Signifor LAR.
- Need for specialist diagnosis and monitoring.
- Use primarily after surgery or prior drug failure.
- Potential need for combination therapy.
- Limited use in patients who can receive curative surgery.
- Competition from orally administered cortisol-lowering agents.
These factors produce a market with high treatment value but limited treatment volume.
What is the FDA regulatory status of Signifor and Signifor LAR?
The FDA approved Signifor immediate release on December 14, 2012, for Cushing’s disease in adults for whom pituitary surgery is not an option or has not been curative.[1]
Signifor LAR was approved for acromegaly in December 2014 for patients who have had an inadequate response to surgery or cannot undergo surgery.[2] The depot product expanded pasireotide’s commercial utility by reducing administration frequency compared with the immediate-release product.
The FDA labeling distinguishes between the two dosage forms. Pasireotide diaspartate is associated with the immediate-release formulation, while the depot product is based on pasireotide pamoate. Regulatory and patent analysis must therefore evaluate the products separately.
| FDA milestone |
Event |
| December 2012 |
Signifor injection approved for Cushing’s disease |
| December 2014 |
Signifor LAR approved for acromegaly |
| Later label expansion |
Signifor LAR developed for longer-term endocrine use, including Cushing’s disease in applicable regulatory jurisdictions |
What patents protect pasireotide diaspartate and Signifor LAR?
Pasireotide protection is likely distributed across several patent categories rather than a single compound patent alone:
- Composition-of-matter patents covering pasireotide or related peptide analogues.
- Salt and solid-state patents covering pasireotide diaspartate or pamoate.
- Formulation patents covering injectable and depot compositions.
- Method-of-use patents covering Cushing’s disease and acromegaly.
- Manufacturing patents covering peptide synthesis, purification, and pharmaceutical preparation.
- Device or presentation rights associated with depot administration.
The key commercial distinction is between immediate-release pasireotide diaspartate and long-acting pasireotide pamoate. A patent estate that protects the active peptide may not independently block a competitor from developing a different salt, formulation, or delivery system after expiration of relevant composition claims.
Public FDA labeling confirms the active ingredients and formulations but does not by itself establish the complete patent estate.[1,2] Orange Book listings, patent term adjustments, pediatric extensions, and litigation records must be checked at the specific product and patent level before determining a precise generic entry date.
Patent strength assessment
| Patent category |
Commercial importance |
Likely vulnerability |
| Core peptide composition |
High |
Expiration and validity challenges |
| Diaspartate formulation |
Medium to high |
Salt and formulation obviousness challenges |
| Pamoate depot formulation |
High for LAR |
Design-around through alternate depot technology |
| Cushing’s disease method |
Medium |
Section 8 carve-out and treatment-practice issues |
| Acromegaly method |
Medium |
Narrow patient population and alternative therapies |
| Manufacturing process |
Medium |
Difficult to detect infringement; process substitution possible |
The strongest practical barrier may be the combination of formulation complexity, limited market size, and manufacturing know-how. Patent expiry alone does not guarantee rapid generic entry for a sterile, peptide-based, depot injectable product.
When does pasireotide lose exclusivity?
A single definitive loss-of-exclusivity date cannot be assigned to all pasireotide products because exclusivity depends on the specific patent, formulation, regulatory pathway, and jurisdiction.
The relevant U.S. protections may include:
- New chemical entity exclusivity tied to the original approval.
- Orphan-drug exclusivity for the approved indication.
- Listed patents in the FDA Orange Book.
- Patent-term restoration or adjustment.
- Formulation and method-of-use patents.
- Potential pediatric exclusivity, if granted.
For commercial forecasting, the relevant date is the earliest date on which a competitor can lawfully market an equivalent product, not merely the expiration of the oldest patent. A generic applicant could challenge listed patents before expiry through an Abbreviated New Drug Application and Paragraph IV certification.
Paragraph IV challenge risk
A Paragraph IV challenge would likely focus on:
- Invalidity of composition or salt claims.
- Lack of novelty or obviousness for the formulation.
- Noninfringement through an alternate salt or delivery system.
- Narrowness of method-of-use claims.
- Failure of the listed patent to cover the proposed generic product.
Immediate-release pasireotide may be more vulnerable to conventional injectable competition than Signifor LAR. The depot product presents greater technical and regulatory complexity, which can delay entry even if a patent challenge succeeds.
What Orange Book status does pasireotide have?
The Orange Book is the primary U.S. source for approved drug products, therapeutic equivalence evaluations, and listed patents. Signifor and Signifor LAR should be analyzed as separate products because they differ in formulation, route, dosage form, and active salt.
An Orange Book review should identify:
- Whether each product has active listed patents.
- The expiry and patent-use codes for those patents.
- Whether patents cover the active ingredient, formulation, or method of use.
- Whether an ANDA has been filed.
- Whether a Paragraph IV notice has triggered litigation.
- Whether the product has a therapeutic-equivalence code that supports substitution.
No broad commercial conclusion should be drawn from the absence of an announced generic. Complex injectable products can remain commercially protected through formulation and manufacturing barriers even when the principal compound patent has expired.
Which companies are challenging pasireotide?
There is no broadly established public record of a major U.S. generic launch or high-profile Paragraph IV litigation against Signifor or Signifor LAR comparable to litigation involving large-volume small-molecule products.
Potential challengers would include generic manufacturers with sterile injectable capabilities, peptide manufacturing expertise, and willingness to serve a small endocrine market. Likely commercial candidates would be companies active in complex generics and specialty injectables rather than high-volume oral-generic manufacturers.
The absence of prominent litigation is commercially meaningful. It suggests that the market may not justify aggressive early entry, or that product-specific patent and technical barriers remain sufficient to deter development.
How has Novartis’s financial trajectory for pasireotide developed?
Novartis does not generally report Signifor or pasireotide revenue as a standalone line item in its public annual reports. The product is included within broader business reporting, which limits direct reconstruction of annual sales, gross margin, and operating profit.[5]
The financial trajectory can therefore be assessed through product lifecycle and market structure rather than a verified standalone revenue series.
Commercial lifecycle
| Period |
Financial interpretation |
| 2012 to 2014 |
Initial commercialization in Cushing’s disease; limited launch population |
| 2014 to 2018 |
Expansion through Signifor LAR and entry into acromegaly |
| 2018 onward |
Mature specialty product with recurring but constrained demand |
| Current lifecycle |
Defended niche product exposed to competition, patent expiry, and portfolio prioritization |
The LAR formulation likely improved adherence and reduced administration burden relative to twice-daily injection. It also expanded the revenue base into acromegaly, where chronic therapy is common. The product did not become a large pharmaceutical franchise because it remained a later-line treatment with significant metabolic liabilities.
Revenue exposure
Pasireotide revenue exposure is concentrated in:
- Endocrinology specialists.
- Rare-disease and specialty-pharmacy channels.
- U.S. and major European markets.
- Patients with surgery failure or contraindication.
- Long-term injectable treatment.
Revenue is less exposed to primary-care prescribing and less dependent on broad promotional reach. The key variables are diagnosis rates, treatment persistence, reimbursement, and the availability of competing endocrine drugs.
How does pasireotide compare with osilodrostat and octreotide?
| Attribute |
Pasireotide |
Osilodrostat |
Octreotide LAR |
| Main target |
Pituitary somatostatin receptors |
Cortisol synthesis pathway |
Somatostatin receptors |
| Major use |
Cushing’s disease and acromegaly |
Cushing’s disease |
Acromegaly and other endocrine indications |
| Administration |
Subcutaneous or depot injection |
Oral |
Long-acting injection |
| Main advantage |
Pituitary-directed activity and multi-receptor binding |
Direct cortisol reduction and oral dosing |
Long clinical history and physician familiarity |
| Main limitation |
Hyperglycemia and injection burden |
Adrenal insufficiency and steroidogenesis-related monitoring |
Incomplete biochemical control in some patients |
| Market position |
Later-line or selected patients |
Increasing Cushing’s disease competitor |
Established acromegaly standard |
Pasireotide has a differentiated mechanism, but differentiation does not remove the need to manage glucose toxicity. In acromegaly, it is generally a second-line option after inadequate control with first-generation somatostatin receptor ligands. In Cushing’s disease, oral cortisol-lowering drugs can be more attractive when rapid systemic cortisol control is the priority.
What generic launch scenarios exist for pasireotide?
Scenario 1: No near-term generic entry
This is the most commercially conservative scenario. A small patient pool, complex injectable manufacturing, and uncertain reimbursement economics could delay development even after key patents expire.
Scenario 2: Immediate-release generic entry
A competitor could target pasireotide diaspartate injection first because the product has a less complex delivery system than the LAR formulation. Price erosion would depend on therapeutic-equivalence approval and the number of entrants.
Scenario 3: LAR formulation challenge
A Signifor LAR competitor would face more substantial formulation, depot-release, sterility, bioequivalence, and manufacturing hurdles. Entry could occur later and with fewer competitors, supporting higher post-entry pricing than a conventional injectable generic.
Scenario 4: Authorized or licensed competition
A licensing transaction, contract manufacturing arrangement, or authorized generic could provide market access without a public Paragraph IV dispute. No major pasireotide licensing transaction is broadly disclosed as a material standalone commercial event in Novartis’s public reporting.
What geographic markets matter most for pasireotide?
The United States is strategically important because of specialty-drug pricing, orphan-disease reimbursement, and the size of the commercial endocrine market. Europe provides additional demand but has country-specific health-technology assessment and reimbursement constraints.
Other markets can contribute volume, but adoption depends on:
- Local approval of the immediate-release and depot formulations.
- Reimbursement for rare endocrine disorders.
- Availability of pituitary surgery and specialist care.
- Local competition from octreotide, lanreotide, pegvisomant, and cortisol-lowering therapies.
- Supply of sterile injectable products.
Geographic patent coverage must be assessed country by country. U.S. patent expiry does not establish European, Japanese, Canadian, or emerging-market entry dates.
How strong is the pasireotide patent estate?
The estate is commercially meaningful but unlikely to create indefinite protection. Compound, salt, formulation, method-of-use, and manufacturing rights can extend protection beyond the initial product approval, but each category has a different scope and enforcement profile.
The strongest protection is likely associated with the depot formulation and manufacturing process. Method-of-use claims may be less effective against treatment of the same disease where clinicians can prescribe a competing drug or use a labeled indication carve-out. The immediate-release product is more exposed to a conventional injectable challenge than the LAR product.
Key Takeaways
- Pasireotide diaspartate is the active ingredient in Signifor immediate-release injection.
- Signifor was FDA-approved in 2012 for adults with Cushing’s disease when surgery is unavailable or unsuccessful.
- Signifor LAR expanded the franchise into acromegaly and long-term depot treatment.
- The commercial market is small, specialist-driven, and concentrated in treatment-resistant patients.
- Hyperglycemia is the principal clinical and commercial limitation.
- Osilodrostat has increased competitive pressure in Cushing’s disease.
- Octreotide LAR and lanreotide remain strong competitors in acromegaly.
- Novartis does not publicly disclose pasireotide sales as a standalone revenue line.
- Generic entry risk is shaped by formulation complexity and market size, not only by compound-patent expiry.
- Immediate-release pasireotide is more exposed to generic competition than the long-acting depot product.
- A precise loss-of-exclusivity date requires product-specific Orange Book and patent records.
FAQs About Pasireotide Diaspartate
Is pasireotide diaspartate the same as pasireotide pamoate?
No. Pasireotide diaspartate is associated with the immediate-release Signifor injection. Pasireotide pamoate is used in the long-acting Signifor LAR depot formulation.
Is pasireotide a biologic drug?
Pasireotide is a synthetic peptide analogue, not a monoclonal antibody or conventional biologic. Its injectable and depot formulations can still create complex regulatory and manufacturing requirements.
Does pasireotide have biosimilar risk?
Traditional biosimilar risk is limited because pasireotide is not a monoclonal antibody or protein biologic regulated through the usual biosimilar pathway. The more relevant risk is a complex generic or follow-on injectable product.
What is the main reason physicians avoid pasireotide?
The main concern is hyperglycemia, which can be clinically significant and may require glucose-lowering treatment or discontinuation. Injection burden and later-line positioning also limit use.
Could pasireotide sales increase without new indications?
Growth could come from improved diagnosis of Cushing’s disease, greater use after failed surgery, increased adoption of the LAR formulation, and combination treatment. The small eligible population and competition from oral cortisol-lowering drugs cap the upside.
References
- U.S. Food and Drug Administration. (2023). Signifor (pasireotide diaspartate) injection prescribing information.
- U.S. Food and Drug Administration. (2023). Signifor LAR (pasireotide pamoate) prescribing information.
- Lacroix, A., et al. (2018). Efficacy and safety of once-monthly pasireotide in Cushing’s disease. The Lancet Diabetes & Endocrinology.
- U.S. Food and Drug Administration. (2020). Isturisa (osilodrostat) prescribing information.
- Novartis AG. (2013–2024). Annual reports and financial results.
